Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

β-Artemether and Lumefantrine Dual Drug Loaded Lipid Nanoparticles: Physicochemical Characterization, Pharmacokinetic Evaluation and Biodistribution Study

Author(s): Kashif Shakeel, Farhan Jalees Ahmad, Ranjit Kumar Harwansh and Mohammad Akhlaquer Rahman*

Volume 10, Issue 3, 2022

Published on: 27 August, 2022

Page: [210 - 219] Pages: 10

DOI: 10.2174/2211738510666220428133532

Price: $65

Abstract

Background: β-artemether (BAT) and lumefantrine (LFT) combination therapies are well recognized for the treatment of malaria. However, the current conventional formulations have several drawbacks.

Objective: The study aims to develop novel lipid nanoparticles (LNP) for efficient delivery of BAT and LFT.

Methods: The LNP were prepared by solvent injection method and optimized by the Box-Behnken experimental design to achieve the desired particle size, maximum entrapment efficiency (EE), and percentage drug release. BAT and LFT in rat plasma were estimated by liquid chromatographytandem mass spectrometry (LC-MS/MS).

Results: Freeze-dried LNP comprised of 78.74% (w/w) lipid, 15.74% (w/w) surfactant, 3.93% (w/w) co-surfactant and 1.57% mannitol with respect to the total inactive components. Mean particle size and zeta potential were found to be 140.22 ± 1.36 nm and -35.23 mv, respectively. EE was 80.60 ± 3.85% for BAT and 69.64 ± 2.63% for LFT. The optimized formulation exhibited a biphasic release profile in phosphate buffer (pH 7.2). In vivo study revealed an increased bioavailability of BAT and LFT from dual drug loaded LNP compared to the pure drug solution. Moreover, the tissue distribution study confirmed the high uptake of both the drugs in the liver and spleen.

Conclusion: The study demonstrated the potential use of the developed formulation for oral administration in the treatment of malaria.

Keywords: Malaria, β-artemether, lumefantrine, solubility, bioavailability, pharmacokinetic, stability

« Previous Next »
Graphical Abstract

[1]
Carballeira NM. New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents. Prog Lipid Res 2008; 47(1): 50-61.
[http://dx.doi.org/10.1016/j.plipres.2007.10.002] [PMID: 18023422]
[2]
Greenwood B, Mutabingwa T. Malaria in 2002. Nature 2002; 415: 670-2.
[3]
Ehrhardt S, Meyer CG. Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria. Ther Clin Risk Manag 2009; 5: 805-15.
[http://dx.doi.org/10.2147/TCRM.S5375] [PMID: 19851528]
[4]
Patil S, Suryavanshi S, Pathak S, Sharma S, Patravale V. Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model. Int J Pharm 2013; 455(1-2): 229-34.
[http://dx.doi.org/10.1016/j.ijpharm.2013.07.033] [PMID: 23886650]
[5]
Nandakumar DN, Nagaraj VA, Vathsala PG, Rangarajan P, Padmanaban G. Curcumin-artemisinin combination therapy for malaria. Antimicrob Agents Chemother 2006; 50(5): 1859-60.
[http://dx.doi.org/10.1128/AAC.50.5.1859-1860.2006] [PMID: 16641461]
[6]
Egunsola O, Oshikoya KA. Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: A systematic review. Malar J 2013; 12(1): 385.
[http://dx.doi.org/10.1186/1475-2875-12-385] [PMID: 24175945]
[7]
Lefèvre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001; 64(5-6): 247-56.
[http://dx.doi.org/10.4269/ajtmh.2001.64.247] [PMID: 11463111]
[8]
Mordi MN, Mansor SM, Navaratnam V, Wernsdorfer WH. Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Br J Clin Pharmacol 1997; 43(4): 363-5.
[http://dx.doi.org/10.1046/j.1365-2125.1997.00573.x] [PMID: 9146847]
[9]
Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46(6): 553-61.
[http://dx.doi.org/10.1046/j.1365-2125.1998.00830.x] [PMID: 9862244]
[10]
Lefevre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Clin Drug Investig 1999; 18(6): 467-80.
[http://dx.doi.org/10.2165/00044011-199918060-00006]
[11]
Olumese P. Guidelines for the treatment of Malaria. World Health Organization 2006.
[12]
Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58(2): 265-78.
[http://dx.doi.org/10.1016/j.ejpb.2004.03.001] [PMID: 15296954]
[13]
Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 2004; 71(2) (Suppl.): 179-86.
[http://dx.doi.org/10.4269/ajtmh.2004.71.179] [PMID: 15331836]
[14]
Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev 2007; 59(7): 667-76.
[http://dx.doi.org/10.1016/j.addr.2007.05.006] [PMID: 17618704]
[15]
Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 1998; 15(1): 11-22.
[http://dx.doi.org/10.1023/A:1011984216775] [PMID: 9487541]
[16]
Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev 2008; 60(6): 625-37.
[http://dx.doi.org/10.1016/j.addr.2007.10.010] [PMID: 18068260]
[17]
Singh AV, Maharjan RS, Kromer C, et al. Advances in smoking related in-vitro inhalation toxicology: A perspective case of challenges and opportunities from progresses in lung-on-chip technologies. Chem Res Toxicol 2021; 34(9): 1984-2002.
[http://dx.doi.org/10.1021/acs.chemrestox.1c00219] [PMID: 34397218]
[18]
Singh AV, Chandrasekar V, Janapareddy P, et al. Emerging application of nanorobotics and artificial intelligence to cross the BBB: Advances in design, controlled maneuvering, and targeting of the barriers. ACS Chem Neurosci 2021; 12(11): 1835-53.
[http://dx.doi.org/10.1021/acschemneuro.1c00087] [PMID: 34008957]
[19]
du Plessis LH, Govender K, Denti P, Wiesner L. In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology. Eur J Pharm Biopharm 2015; 97(Pt A): 68-77.
[http://dx.doi.org/10.1016/j.ejpb.2015.10.001] [PMID: 26478276]
[20]
Agbo C, Umeyor C, Kenechukwu F, et al. Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. Drug Dev Ind Pharm 2016; 42(10): 1708-21.
[http://dx.doi.org/10.3109/03639045.2016.1171331] [PMID: 27095388]
[21]
Singh A, Ahmad I, Akhter S, et al. Nanocarrier based formulation of Thymoquinone improves oral delivery: Stability assessment, in vitro and in vivo studies. Colloids Surf B Biointerfaces 2013; 102: 822-32.
[http://dx.doi.org/10.1016/j.colsurfb.2012.08.038] [PMID: 23104039]
[22]
Martin OO, Elizabeth J, Caroline GK, et al. A selective LC-MS/MS method for simultaneous quantification of artemether, lumefantrine and their principal metabolites in human plasma. ABC Research Alert 2018; 6: 186-201.
[23]
Kriegel FL, Krause BC, Hachenberger YU, et al. ICP-MS-based approach to determine nanoparticle recovery after hollow fiber flow field flow fractionation. Curr Med Chem 2022; 29(2): 358-68.
[http://dx.doi.org/10.2174/0929867328666210222094913] [PMID: 33618638]
[24]
Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: Preparation and neuropharmacological evaluation. Nanomedicine 2009; 5(3): 323-33.
[http://dx.doi.org/10.1016/j.nano.2008.12.003] [PMID: 19523427]
[25]
Burdock GA, Carabin IG, Griffiths JC. The importance of GRAS to the functional food and nutraceutical industries. Toxicology 2006; 221(1): 17-27.
[26]
Williams GM, Kobets T, Iatropoulos MJ, Duan JD, Brunnemann KD. GRAS determination scientific procedures and possible alternatives. Regul Toxicol Pharmacol 2016; 79 (Suppl. 2): S105-11.
[http://dx.doi.org/10.1016/j.yrtph.2016.06.015] [PMID: 27328372]
[27]
Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28(1): 56-63.
[http://dx.doi.org/10.1093/ajcp/28.1.56] [PMID: 13458125]
[28]
Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 2010; 17(7): 467-89.
[http://dx.doi.org/10.3109/10717544.2010.483257] [PMID: 20491540]

Rights & Permissions Print Cite
Article Metrics
9
© 2024 Bentham Science Publishers | Privacy Policy